VFA
CRDF icon

Valeo Financial Advisors’s Cardiff Oncology CRDF Stock Holding History

Valeo Financial Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,250
Closed -$21K – 782
2021
Q1 		$21K Buy
+2,250
New +$27.3K ﹤0.01% 1141

Other funds holding CRDF

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Valeo Financial Advisors's CRDF Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Cardiff Oncology (CRDF) in Q2 2021, closing a stake of 2,250 shares — an estimated $21K sold.

Valeo Financial Advisors first reported a position in CRDF in Q1 2021 and held it in 1 quarter. The position peaked at $21K in Q1 2021. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Cardiff Oncology position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 2,250 Cardiff Oncology shares in Q2 2021, an estimated $21K.
  • Valeo Financial Advisors first reported a position in Cardiff Oncology in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's Cardiff Oncology position peaked at $21K in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.